Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 6 of 6
Full-Text Articles in Medicine and Health Sciences
Device Assessed Activity Behaviours In Patients With Indwelling Pleural Catheter: A Sub-Study Of The Australasian Malignant Pleural Effusion (Ample)-2 Randomized Trial, Carolyn J. Peddle-Mcintyre, Sanjeevan Muruganandan, Joanne Mcveigh, Deirdre B. Fitzgerald, Leon Straker, Robert U. Newton, Kevin Murray, Yun Chor Gary Lee
Device Assessed Activity Behaviours In Patients With Indwelling Pleural Catheter: A Sub-Study Of The Australasian Malignant Pleural Effusion (Ample)-2 Randomized Trial, Carolyn J. Peddle-Mcintyre, Sanjeevan Muruganandan, Joanne Mcveigh, Deirdre B. Fitzgerald, Leon Straker, Robert U. Newton, Kevin Murray, Yun Chor Gary Lee
Research outputs 2022 to 2026
Background and Objective: Device-assessed activity behaviours are a novel measure for comparing intervention outcomes in patients with malignant pleural effusion (MPE). Australasian Malignant PLeural Effusion (AMPLE)-2 was a multi-centre clinical trial where participants with MPE treated with an indwelling pleural catheter were randomized to daily (DD) or symptom-guided (SGD) drainage for 60-days. Our aim was to describe activity behaviour patterns in MPE patients, explore the impact of drainage regimen on activity behaviours and examine associations between activity behaviours and quality of life (QoL). Methods: Following randomization to DD or SGD, participants enrolled at the lead site (Perth) completed accelerometry assessment. …
Non-Pharmacological Self-Management Strategies For Chemotherapy-Induced Peripheral Neuropathy In People With Advanced Cancer: A Systematic Review And Meta-Analysis, Megan Crichton, Patsy M. Yates, Oluwaseyifunmi Andi Agbejule, Amy Spooner, Raymond J. Chan, Nicolas H. Hart
Non-Pharmacological Self-Management Strategies For Chemotherapy-Induced Peripheral Neuropathy In People With Advanced Cancer: A Systematic Review And Meta-Analysis, Megan Crichton, Patsy M. Yates, Oluwaseyifunmi Andi Agbejule, Amy Spooner, Raymond J. Chan, Nicolas H. Hart
Research outputs 2022 to 2026
Non-pharmacological self-management interventions for chemotherapy-induced peripheral neurotherapy (CIPN) are of clinical interest; however, no systematic review has synthesized the evidence for their use in people with advanced cancer. Five databases were searched from inception to February 2022 for randomized controlled trials assessing the effect of non-pharmacological self-management interventions in people with advanced cancer on the incidence and severity of CIPN symptoms and related outcomes compared to any control condition. Data were pooled with metaanalysis. Quality of evidence was appraised using the Revised Cochrane Risk of Bias Tool for Randomized Trials (RoB2), with data synthesized narratively. Grading of Recommendations, Assessment, Development …
Survivorship Research For People With Metastatic Or Advanced Cancer: A Time For Action, Andrea L. Smith, Nicolas H. Hart, Michael Jefford, Raymond J. Chan
Survivorship Research For People With Metastatic Or Advanced Cancer: A Time For Action, Andrea L. Smith, Nicolas H. Hart, Michael Jefford, Raymond J. Chan
Research outputs 2022 to 2026
Over recent decades, survival outcomes for people diagnosed with cancer have changed dramatically, with approximately 20% improvement in five-year relative survival rates in high-income countries including the United States and Australia. Regardless of regions, there is a decrease in overall cancer mortality rate of about 1% per year. Likewise, the cancer disease trajectory has changed. The traditional linear cancer trajectory in which a patient moves from cancer diagnosis through to a binary outcome (cure or death)—is no longer applicable and does not adequately describe the complexity of experience for many people. Indeed, the availability of targeted therapies and immunotherapies has …
Deciding To Enrol In A Cancer Trial: A Systematic Review Of Qualitative Studies, Bianca Viljoen, Suzanne K. Chambers, Jeff Dunn, Nicholas Ralph, Sonja March
Deciding To Enrol In A Cancer Trial: A Systematic Review Of Qualitative Studies, Bianca Viljoen, Suzanne K. Chambers, Jeff Dunn, Nicholas Ralph, Sonja March
Research outputs 2014 to 2021
© 2020 Viljoen et al. Background: Clinical trials are essential for the advancement of cancer treatments; how-ever, participation by patients is suboptimal. Currently, there is a lack of synthesized qualitative review evidence on the patient experience of trial entry from which to further develop decision support. The aim of this review is to synthesise literature reporting experiences of participants when deciding to enrol in a cancer clinical trial in order to inform practice. Methods: A systematic review and meta-synthesis of qualitative studies were conducted to describe the experiences of adult cancer patients who decided to enrol in a clinical trial …
Mechanical Suppression Of Osteolytic Bone Metastases In Advanced Breast Cancer Patients: A Randomised Controlled Study Protocol Evaluating Safety, Feasibility And Preliminary Efficacy Of Exercise As A Targeted Medicine, Nicolas H. Hart, Daniel A. Galvão, Christobel Saunders, Dennis R. Taaffe, Kynan T. Feeney, Nigel A. Spry, Daphne Tsoi, Hilary Martin, Raphael Chee, Tim Clay, Andrew D. Redfern, Robert U. Newton
Mechanical Suppression Of Osteolytic Bone Metastases In Advanced Breast Cancer Patients: A Randomised Controlled Study Protocol Evaluating Safety, Feasibility And Preliminary Efficacy Of Exercise As A Targeted Medicine, Nicolas H. Hart, Daniel A. Galvão, Christobel Saunders, Dennis R. Taaffe, Kynan T. Feeney, Nigel A. Spry, Daphne Tsoi, Hilary Martin, Raphael Chee, Tim Clay, Andrew D. Redfern, Robert U. Newton
Research outputs 2014 to 2021
BACKGROUND: Skeletal metastases present a major challenge for clinicians, representing an advanced and typically incurable stage of cancer. Bone is also the most common location for metastatic breast carcinoma, with skeletal lesions identified in over 80% of patients with advanced breast cancer. Preclinical models have demonstrated the ability of mechanical stimulation to suppress tumour formation and promote skeletal preservation at bone sites with osteolytic lesions, generating modulatory interference of tumour-driven bone remodelling. Preclinical studies have also demonstrated anti-cancer effects through exercise by minimising tumour hypoxia, normalising tumour vasculature and increasing tumoural blood perfusion. This study proposes to explore the promising …
Circulating Tumor Dna To Monitor Treatment Response And Detect Acquired Resistance In Patients With Metastatic Melanoma, Elin S. Gray, Helen Rizos, Anna L. Reid, Suzanah Boyd, Michelle Pereira, Johnny Lo, Varsha Tembe, James Freeman, Jenny Lee, Richard Scolyer, Kelvin Siew, Chris Lomma, Adam Cooper, Muhammad Khattak, Tarek Meniawy, Georgina Long, Matteo Carlino, Michael Millward, Mel R. Ziman
Circulating Tumor Dna To Monitor Treatment Response And Detect Acquired Resistance In Patients With Metastatic Melanoma, Elin S. Gray, Helen Rizos, Anna L. Reid, Suzanah Boyd, Michelle Pereira, Johnny Lo, Varsha Tembe, James Freeman, Jenny Lee, Richard Scolyer, Kelvin Siew, Chris Lomma, Adam Cooper, Muhammad Khattak, Tarek Meniawy, Georgina Long, Matteo Carlino, Michael Millward, Mel R. Ziman
Research outputs 2014 to 2021
Repeat tumor biopsies to study genomic changes during therapy are difficult, invasive and data are confounded by tumoral heterogeneity. The analysis of circulating tumor DNA (ctDNA) can provide a non-invasive approach to assess prognosis and the genetic evolution of tumors in response to therapy. Mutation-specific droplet digital PCR was used to measure plasma concentrations of oncogenic BRAF and NRAS variants in 48 patients with advanced metastatic melanoma prior to treatment with targeted therapies (vemurafenib, dabrafenib or dabrafenib/trametinib combination) or immunotherapies (ipilimumab, nivolumab or pembrolizumab). Baseline ctDNA levels were evaluated relative to treatment response and progression-free survival (PFS). Tumor-associated ctDNA was …